Related Experiment Videos
Bacillus Calmette-Guerin immunotherapy for bladder cancer
The Journal of Urology
|July 1, 1985
Summary
Bacillus Calmette-Guerin immunotherapy effectively prevents superficial bladder cancer recurrence. Positive purified protein derivative skin tests predict a better response, indicating its utility in optimizing treatment protocols.
Area of Science:
- Urology
- Immunotherapy
- Oncology
Background:
- Superficial bladder cancer poses a significant challenge in treatment and prevention.
- Bacillus Calmette-Guerin (BCG) immunotherapy is recognized for its efficacy in managing this condition.
- Optimal treatment protocols for BCG immunotherapy require further refinement.
Purpose of the Study:
- To evaluate the long-term effectiveness of Bacillus Calmette-Guerin (BCG) immunotherapy in treating and preventing superficial bladder cancer.
- To identify factors, such as skin test reactivity, that predict patient response to BCG immunotherapy.
- To assess the impact of treatment duration and frequency on BCG efficacy and side effects.
Main Methods:
- Analysis of data from 92 randomized and 30 nonrandomized patients with superficial bladder cancer, followed for up to 5 years.
- Comparison of tumor recurrence rates between patients treated with BCG and control groups.
- Evaluation of the correlation between purified protein derivative (PPD) skin test reactivity and treatment outcomes.
Main Results:
- BCG treatment significantly reduced tumor recurrence (20% vs. 52% in controls, p=0.008) and increased time to recurrence (24 to 48 months).
- Patients with a positive conversion of PPD skin test results showed a substantially lower recurrence rate (4.5%) compared to those with persistently positive or negative tests.
- Percutaneous BCG demonstrated potential benefits, with lower recurrence rates observed in patients receiving it.
- High-risk patients, including those with prior chemotherapy or carcinoma in situ, showed significant tumor recurrence reduction or complete response with BCG.
Conclusions:
- Bacillus Calmette-Guerin immunotherapy is a highly effective treatment for superficial bladder cancer, significantly reducing recurrence rates.
- Purified protein derivative skin test reactivity serves as a valuable predictive marker for BCG immunotherapy response.
- Further research into optimal BCG protocols, considering treatment duration, frequency, and administration routes, is warranted to maximize efficacy and minimize side effects.